Clinical trial
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous…
NCT00003758 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Unknown status
Key facts
| NCT number | NCT00003758 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia |
| Official title | Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | cytarabine, idarubicin, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation |
| Enrollment | 60 |
| Start date | Dec 1, 1998 |
| First posted | Jun 3, 2004 |
| Last update posted | Feb 9, 2009 |
| Countries | Belgium, Croatia, France, Italy, Netherlands, Portugal, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: